341 related articles for article (PubMed ID: 32897034)
1. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD; Haworth CS; Metersky ML; Loebinger MR; Blasi F; Sibila O; O'Donnell AE; Sullivan EJ; Mange KC; Fernandez C; Zou J; Daley CL;
N Engl J Med; 2020 Nov; 383(22):2127-2137. PubMed ID: 32897034
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
Chalmers JD; Usansky H; Rubino CM; Teper A; Fernandez C; Zou J; Mange KC
Clin Pharmacokinet; 2022 Oct; 61(10):1457-1469. PubMed ID: 35976570
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.
Usansky H; Yoon E; Teper A; Zou J; Fernandez C
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):832-842. PubMed ID: 35411669
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.
Keir HR; Long MB; Abo-Leyah H; Giam YH; Vadiveloo T; Pembridge T; Hull RC; Delgado L; Band M; McLaren-Neil F; Adamson S; Lahnsteiner E; Gilmour A; Hughes C; New BJ; Connell D; Dowey R; Turton H; Richardson H; Cassidy D; Cooper J; Suntharalingam J; Diwakar L; Russell P; Underwood J; Hicks A; Dosanjh DP; Sage B; Dhasmana D; Spears M; Thompson AR; Brightling C; Smith A; Patel M; George J; Condliffe AM; Shoemark A; MacLennan G; Chalmers JD;
Lancet Respir Med; 2022 Dec; 10(12):1119-1128. PubMed ID: 36075243
[TBL] [Abstract][Full Text] [Related]
6. Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis.
Gunsolley JC; Chalmers JD; Sibila O; Fernandez C; Scannapieco FA
JDR Clin Trans Res; 2023 Sep; ():23800844231196884. PubMed ID: 37746735
[TBL] [Abstract][Full Text] [Related]
7. A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation.
Shoemark A; Cant E; Carreto L; Smith A; Oriano M; Keir HR; Perea L; Canto E; Terranova L; Vidal S; Moffitt K; Aliberti S; Sibila O; Chalmers JD
Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 31151955
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects.
Palmér R; Mäenpää J; Jauhiainen A; Larsson B; Mo J; Russell M; Root J; Prothon S; Chialda L; Forte P; Egelrud T; Stenvall K; Gardiner P
Clin Pharmacol Ther; 2018 Dec; 104(6):1155-1164. PubMed ID: 29484635
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.
Chalmers JD; Moffitt KL; Suarez-Cuartin G; Sibila O; Finch S; Furrie E; Dicker A; Wrobel K; Elborn JS; Walker B; Martin SL; Marshall SE; Huang JT; Fardon TC
Am J Respir Crit Care Med; 2017 May; 195(10):1384-1393. PubMed ID: 27911604
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial.
Watz H; Nagelschmitz J; Kirsten A; Pedersen F; van der Mey D; Schwers S; Bandel TJ; Rabe KF
Pulm Pharmacol Ther; 2019 Jun; 56():86-93. PubMed ID: 30917927
[TBL] [Abstract][Full Text] [Related]
13. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
14. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
Chen KJ; Zhang J; LaSala D; Basso J; Chun D; Zhou Y; McDonald PP; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1185727. PubMed ID: 37441081
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Basso J; Chen KJ; Zhou Y; Mark L; LaSala D; Dorfman A; Atalla M; Chun D; Viramontes V; Chang C; Leifer F; McDonald PP; Cipolla DC
Front Pharmacol; 2023; 14():1208780. PubMed ID: 37538173
[TBL] [Abstract][Full Text] [Related]
16. Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
McDonald PP; Leifer FG; Basso J; Lasala D; Li D; Chen KJ; Zhang J; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1231047. PubMed ID: 37638021
[TBL] [Abstract][Full Text] [Related]
17. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
[TBL] [Abstract][Full Text] [Related]
18. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG
Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study.
Jayaram L; King PT; Hunt J; Lim M; Park C; Hu E; Dousha L; Ha P; Bartlett JB; Southcott AM; Muruganandan S; Vogrin S; Rees MA; Dean OM; Wong CA
Pulm Pharmacol Ther; 2024 Mar; 84():102283. PubMed ID: 38141851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
